Kyorin Pharmaceutical, Novartis AG Enter into Licensing Agreement for Immunosuppressant KRP-203.Tokyo, Japan, Feb 17, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kyorin Pharmaceutical announced on February 16 that it has signed a licensing agreement with Novartis AG Novartis AG Swiss pharmaceutical company. It was formed through the 1996 merger of two Swiss firms: Ciba (see Ciba-Geigy) and Sandoz, a chemical company with interests in pharmaceuticals, nutrition, and agriculture. for KRP-203, an immunosuppressant immunosuppressant /im·mu·no·sup·pres·sant/ (-sah-pres´ant) an agent capable of suppressing immune responses. im·mu·no·sup·pres·sant n. An agent that suppresses the body's immune response. developed by Kyorin. Under the agreement terms, Kyorin grants Novartis with exclusive rights to develop and commercialize KRP-203 worldwide for use in organ transplants as well as an exclusive right to develop and commercialize KRP-203 worldwide except in Japan, Korea, China and Taiwan for the treatment of autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause and other diseases. As for the treatment of inflammatory bowl disease. Kyorin keeps a worldwide exclusive right to KRP-203. Kyorin Pharmaceutical announced on February 16 that it has signed a licensing agreement with Novartis AG for KRP-203, an immunosuppressant developed by Kyorin. KRP-203 is a sphingosine-1-phosphate receptor antagonist with a novel chemical structure. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion